GATC's advanced AI platform
predicts outcomes of early-stage drug candidates
with true positive rate of 86% and true negative rate of 91%,
potentially saving billions in lost drug development costs and
significantly decreasing risk for drug R&D.
IRVINE,
Calif., May 16, 2024 /PRNewswire/ -- GATC Health
Corp, a technology company advancing drug discovery and disease
prediction using artificial intelligence (AI), has
successfully completed two external AI platform
validation tests in collaboration with a pharmaceutical science lab
at University of California, Irvine's
(UCI). UCI specifically designed the tests to
independently verify the performance of GATC Health's AI's primary
drug screening capabilities and provide unique and detailed
insights into drug success risks. The successful outcome of the
tests mark a significant milestone in the advancement of AI in drug
discovery.
The results provide further validation of the ability of GATC's
AI platform to effectively measure safety, efficacy, and off-target
effects in early-stage drug candidates, which are key indicators of
successful phase 1 and phase 2 clinical trials. The study
confirmed, and in some cases exceeded, GATC's own internal
retrospective double-blinded analysis completed in September 2023, which successfully demonstrated a
true positive rate of 86% and a true negative rate of 84%. This
internal study analyzed over 14,000 compounds with known outcomes
across hundreds of disease states.
"GATC's ability to predict and measure the likelihood of a
potential drug successfully treating a specific disease target and
also whether that drug candidate has safety risks will provide
pharmaceutical companies and investors with a break-through tool
for making billion-dollar decisions," said Dr. Tomas Philipson, former Acting Chairman of the
White House Council of Economic Advisers and former senior economic
advisor to the Commissioner of the Food and Drug Administration.
Dr. Philipson also serves as an advisor to GATC Health.
The company's AI screening process comprises three steps,
collectively aimed at predicting and enhancing the efficiency and
safety of drug discovery:
Safety Screening: Leveraging AI predictions to screen for toxic,
or other negative activation on biological targets, this step is
crucial in assessing the safety and potential side effects of a
drug molecule.
Efficacy Screening: AI predictions are employed to screen for
positive activation on intended and unintended targets using a
combination of simulation and reverse docking AI on broad
biological targets, playing a key role in assessing the efficacy of
a drug molecule, along with a secondary evaluation of side
effects.
Optimized Screening: Post-initial screening steps, predictions
by the AI are made after the GATC platform and its team have
acquired knowledge about the molecules being researched. Additional
optimizations lead to results that often outperform blind, verified
outcomes from UCI, as reflected in internal studies on AI
performance.
The external tests administered by UCI rigorously adhered to
GATC Health's screening process, presenting molecules and their
activity known only to the UCI lab. GATC received only the
chemistry of these molecules before providing predictions to UCI on
a predetermined set of biological targets. It is noteworthy that
the testing of Optimized Screening was not included in the UCI
tests.
"By modeling human systems biology and molecular target activity
in unique ways, our platform uncovers non-obvious solutions that
accelerate all aspects of drug discovery," said Jayson Uffens, Chief Technical Officer and
co-founder of GATC Health. "Having a high degree of confidence in
the predicted human outcomes for known and novel compounds allows
GATC and our partners to make decisions leading to higher quality
and lower risk therapeutics."
Methodology:
Following the delivery of predictions by the GATC platform to UCI,
the activation data was shared with GATC as the answer key for the
test. The Initial Screening was performed in two separate tests
against two sets of AI models in the GATC Platform, resulting in
independently verified test results of 91% for the Specificity Test
(true positive) and 86% for the Sensitivity Test (true negative).
Data used for this independent study consisted of over 4,600
molecules between the two tests.
These successful external tests underscore the reliability of
the GATC Platform's screening capabilities, affirming its potential
to revolutionize the drug discovery landscape. GATC Health remains
committed to advancing AI-driven solutions that expedite and
optimize the drug discovery process for the benefit of patients
globally.
About GATC Health
GATC Health Corp is a technology
company revolutionizing disease prediction and drug discovery and
development through its transformative AI platform and approach,
which de-risks drug pipelines and accelerates new therapies to
treat disease with accuracy, efficiency and speed never before
achieved in medical science. The company's validated and
proprietary Multiomics Advanced Technology™ (MAT) platform
simulates human biochemistry's billions of interactions for
accurate and rapid disease prediction, novel target identification,
and drug discovery and development. GATC envisions the future of
medicine now, where health is protected, disease is reversed and
every person's unique biology is treated with precision.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/university-of-california-irvine-verifies-gatc-healths-ability-to-predict-drug-efficacy-safety-and-off-target-effects-302147239.html
SOURCE GATC Health Corp